Search results
Found 394 matches for
Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?
Mohammadali Yavari Ramsheh
Mohammadali Yavari Ramsheh - Postdoctoral Research Associate in Bioinformatics
Aleksandra Boikova
Aleksandra Boikova - Novo Nordisk Postdoctoral Research Fellow
Alex Clarke
PhD FRCP Alex Clarke - Principal Investigator and Honorary Consultant Rheumatologist, Nuffield Orthopaedic Centre
Adrien Hallou
MSc (Paris) MPhil PhD (Cambridge) Adrien Hallou - Group Leader in Tissue Biology (Innovation Investigator Track)
KC Park
BSc (Hons) DPhil AFHEA KC Park - British Heart Foundation Immediate Research Fellow in Cardio-Oncology
Magdalena Gross
Magdalena Gross - Administration Assistant (Meetings, Events, and Communications)
Christoffer Lagerholm
Christoffer Lagerholm - Advanced Microscopy Scientist (Maternity Cover)
Christian Bucher
Christian Bucher - Postdoctoral Research Associate in Inflammatory Disease
Johannes Lehmann
Johannes Lehmann - Digital Pathology Omics Core Facility Manager
Alice Robinson
MBioSci Alice Robinson - Research Assistant in Cellular and Molecular Biology
